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ever, better to have all metal areas where the disc hits the
struts polished, as in all other patients (patients 4-12).
The area adjacent to the suture ring is the important place
to have a microporous surface to bind down the covering
from the suture ring. After 11 to 13 years of follow-up of 12
patients with the Björk-Shiley Monostrut mechanical mitral
valve with a microporous surface and without anticoagula-
tion, 9 children have been born and no thromboembolic com-
plications have been encountered.
Summary. This microporous surface will be covered in 3
months by a thin, smooth, glistening endothelium, free from
excrescence formation and fibrin precipitation, extending
over the groove and adjacent part of the suture ring. Thus the
thicker fibrous covering over the suture ring will be connect-
ed with the microporous covering. This will prevent a throm-
botic protrusion into the valve orifice with risk for emboli. As
the Monostrut valve has been accepted by the Food and Drug
Administration after 16 years of successful clinical use, the
results achieved from this pilot study indicate the necessity of
a multicenter study, the outcome of which could solve valve
surgery problems, especially for young girls.
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A fatal mechanical disorder of the TCI HeartMate
left ventricular assist system
To the Editor:
The HeartMate vented electric (VE) left ventricular assist
system (LVAS) (TCI; Thermo Cardiosystems Inc, Woburn,
Mass) has been used in more than 1400 patients worldwide and
in 42 patients in our hospital since November 1995. We expe-
rienced a case of fatal mechanical disorder with this device,
which required an emergency exchange of the LVAS. The
patient was a 34-year-old man who had undergone implanta-
tion of the HeartMate VE LVAS because of dilative cardiomy-
opathy more than 1 year earlier. He was referred to us twice for
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Fig 1. Clotted blood was seen in the whole LVAS motor chamber, which prevented the pump from working.
problems with a cable. In both events, the LVAS worked nor-
mally and the patient’s condition was stable. The cable was
thoroughly examined and repaired by a technician from TCI.
Four days after the second cable repair, the red alarm suddenly
warned at home. The manual mechanical pumping with the
hand pump was immediately initiated by the patient himself,
and he was transferred to our hospital urgently by helicopter.
During the transport his condition worsened and he needed to
be intubated. This emergency occurred 380 days after the
LVAS implantation. The LVAS could still work with the pneu-
matic system, so that his hemodynamic condition was well
controlled with dopamine perfusion. The problem with the
LVAS was studied by a technician from TCI. Because dried
bloodlike material was observed in the hand pump and the
stroke volume limiter connecting tube, we suspected a rupture
of the drive line or the diaphragm separating the blood pump
chamber from the motor chamber in the LVAS. We exchanged
the LVAS through the incision in the abdominal pocket with
cardiopulmonary bypass established through the femoral artery
and vein. The postoperative course was excellent. He was dis-
charged to his home on postoperative day 24 and is now wait-
ing for heart transplantation. The explanted pump was careful-
ly examined. The motor chamber was filled with clotted dried
blood, which prevented the motor/cam assembly from working
(Fig 1). However, by macroscopic observation we could not
find any tears or holes in the diaphragm. The pump was sent
to TCI for precise inspection. TCI’s technicians detected small
tears at the rim of the diaphragm, which might have been
caused by mechanical fatigue. 
The TCI HeartMate LVAS is one of the most reliable sys-
tems in the world.1,2 We have implanted the pneumatic
HeartMate LVAS in 14 patients since April 1994 and the VE
HeartMate LVAS in 28 patients since November 1995.3 A
similar device disorder with the VE HeartMate LVAS was
reported by Piccione and colleagues4 in 1998. They showed,
as in this report, that the motor chamber filled with clotted
blood. However, they could not find any perforation on the
drive line, and they did not refer to the diaphragm. To our
knowledge, this is the first report of a disorder of the
diaphragm in the pump with the VE HeartMate LVAS. The
support time of this patient was 380 days. This long support
time might be one of the reasons for this defect. 
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A word of caution in extrapolating the spinal cord
protective effects of memantine obtained in a rabbit
model under ketamine anesthesia
To the Editor:
We read with great interest the article titled “Memantine
for Prevention of Spinal Cord Injury in a Rabbit Model” by
Ehrlich and associates (J Thorac Cardiovasc Surg 1999;117:
285-91). We do not doubt the protective effects exhibited by
memantine, a noncompetitive N-methyl-D-aspartate (NMDA)
receptor antagonist, and we believe it is a significant contri-
bution to central nervous system protection.
However, we would like to bring a few points to the atten-
tion of the readership:
1. The protective effects of NMDA antagonists are widely
known.1 Part of that protection is due to the hypothermic
effect of NMDA antagonists.2 In any study to assess protec-
tion, specifying only the ischemic time is not enough; speci-
fying the temperature as well, preferably the esophageal tem-
perature, is almost mandatory.
2. The temperature was monitored rectally and, although a
heating pad was used to maintain normal body temperature,
it would have been informative to specify the temperature
itself. We have found that esophageal temperatures more
closely reflect spinal cord temperatures than do rectal tem-
peratures.3 Rectal temperatures are usually higher than
esophageal temperatures, sometimes by as much as 0.5°C to
1.2°C, and esophageal temperature differences as small as
0.5°C might result in totally different neurologic outcomes.2,3
3. Their anesthesia protocol included ketamine, which
resulted in instant loss of transcranial motor-evoked poten-
tials. This can be explained on the basis of the known NMDA
receptor antagonism of ketamine, which is responsible for the
reported protective effects.1,4 Thus the observed protective
effects of memantine were the result of the effects of meman-
tine by itself in addition to those contributed by ketamine, but
their relative roles are unknown. For definitive assessment of
the protective effects of memantine alone, a group of rabbits
anesthetized with nonprotective concentrations of volatile
agents without ketamine or barbiturates is essential before the
data can be extrapolated to human application, because keta-
mine is no longer widely used in humans.
4. Obviously, slow intravenous infusion of memantine over
a 30-minute period before ischemia resulted in better protec-
tion than a fast (3-minute) intra-arterial infusion into the aorta
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